The Maximum Tolerated Dose and to Evaluate Safety and Efficacy of Belinostat (PXD-101) in Combination With Paclitaxel Plus Carboplatin in Chemotherapy-Naive Patients With Stage IV Non-Small-Cell Lung Cancer (NSCLC)

Trial Profile

The Maximum Tolerated Dose and to Evaluate Safety and Efficacy of Belinostat (PXD-101) in Combination With Paclitaxel Plus Carboplatin in Chemotherapy-Naive Patients With Stage IV Non-Small-Cell Lung Cancer (NSCLC)

Completed
Phase of Trial: Phase I/II

Latest Information Update: 25 Sep 2015

At a glance

  • Drugs Belinostat (Primary) ; Carboplatin; Paclitaxel
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions
  • Sponsors Spectrum Pharmaceuticals
  • Most Recent Events

    • 22 Sep 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 19 Mar 2015 Planned End Date changed from 1 Dec 2014 to 1 May 2015 as reported by ClinicalTrials.gov record.
    • 19 Mar 2015 Planned primary completion date changed from 1 Dec 2014 to 1 May 2015 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top